



## **ELBIT MEDICAL IMAGING ANNOUNCES A SPECIAL INTEREST PAYMENT IN CONNECTION WITH ITS SERIES D NOTES**

**Tel Aviv, Israel, August 27, 2007, Elbit Medical Imaging Ltd.** ("EMI") (NASDAQ: EMITF), announced today that, in accordance with EMI's undertakings to pay additional interest of 0.5% per annum to the interest rate borne by the Series D Notes so long as EMI did not publish a prospectus for the listing of Series D Notes for trade on the Tel Aviv Stock Exchange ("TASE"), and following the publication of such a prospectus in Israel today by EMI, EMI intends to pay the holders of Series D Notes a special interest payment of 0.2027%, linked to increases in the Israeli consumer price index, on the unpaid principal of Series D Notes (the "Special Interest") for the period commencing on April 1, 2007 (the day on which Series D Notes were issued) and ending on August 27, 2007 (the date of publication of the above prospectus), including.

The Special Interest will be paid to the holders of Series D Notes at the end of the trading day on the TASE on September 2, 2007. The date of payment of the Special Interest will be September 16, 2007.

The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

### **About Elbit Medical Imaging Ltd.**

EMI is a subsidiary of Europe Israel (M.M.S.) Ltd. EMI's activities are divided into the following principal fields: (i) Initiation, construction, operation, management and sale of shopping and entertainment centers in Israel, Central and Eastern Europe and India; (ii) Hotels ownership, primarily in major European cities, as well as operation, management and sale of same through its subsidiary, Elscint Ltd.; (iii) Investments in the research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, through its subsidiary, InSightec Ltd.; and (iv) Other activities consisting of the distribution and marketing of women's fashion and accessories through our wholly-owned Israeli subsidiary, Mango Israel Clothing and Footwear Ltd., and venture-capital investments.

*Any forward looking statements with respect to EMI's business, financial condition and results of operations included in this release are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward looking statements, including, but not limited to, ability to find suitable locations, receipt of approvals and permits for zoning and construction, delays in construction, dependency on partners in the hotels business, competition, risks relating to operations in Eastern Europe and Asia (including India) and risks relating to our image guided treatment,*

*economic conditions, as well as certain other risk factors which are detailed from time to time in EMI's filings with the Securities and Exchange Commission including, without limitation, Annual Report on Form 20-F for the fiscal year ended December 31, 2006, filed with the Securities and Exchange Commission on July 3, 2007.*

**For Further Information:**

**Company Contact**

Shimon Yitzhaki, President  
Elbit Medical Imaging Ltd.  
(972-3) 608-6000  
syitzhaki@elbitimaging.com

**Investor Contact**

Rachel Levine  
The Global Consulting Group  
1-646-284-9439  
rlevine@hfgcg.com

Dudi Machlof, CFO  
Elbit Medical Imaging Ltd.  
(972-3) 608-6024  
dudim@elbitimaging.com